Top Markets
Coin of the day
Mydecine Innovations Group Inc. Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc.

MYCO
Rangering i aksjer #30738
Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise... Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise dedicated to advancing and commercializing therapies for a range of mental health conditions. The company specializes in developing treatments for specific populations, including veterans, emergency medical service providers, frontline workers, and individuals affected by post-traumatic stress disorder. It also operates Mindleap, an online telehealth platform offering mental wellness services and support for psychedelic integration, including aftercare. Furthermore, Mydecine engages in drug discovery, developing nature-derived psychedelic-assisted therapeutics, novel compounds, specific therapy protocols, and unique drug delivery systems. The company also manages a hemp cultivation facility in Pottus, Texas. Strategic collaborations include alliances with Leiden University Medical Center, Royal Ottawa Mental Health Centre, and LeadGen Labs for psychedelic drug development, as well as Applied Pharmaceutical Innovation for drug development and clinical trial programs. Founded in 2013, the company, originally known as NewLeaf Brands Inc., rebranded as Mydecine Innovations Group Inc. in June 2020 and is headquartered in Vancouver, Canada.
Aksjekurs
$0.25687791
Sist synkronisert: 2026-01-13
Markedsverdi
$15.72M
Endring (1 dag)
100.54%
Endring (1 år)
6,975.98%
Land
CA
Handel Mydecine Innovations Group Inc. (MYCO)

Kategori

P/B-forhold for Mydecine Innovations Group Inc. (MYCO)
P/B-forhold per 2026 TTM: 0
Ifølge Mydecine Innovations Group Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Mydecine Innovations Group Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter